# reload+after+2024-01-20 17:45:42.531444
address1§1800 Kraft Drive
address2§Suite 216
city§Blacksburg
state§VA
zip§24060
country§United States
phone§540 218 1767
website§https://landosbiopharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
fullTimeEmployees§22
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Gregory  Oakes', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1035787, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy M. Mayleben M.B.A.', 'age': 62, 'title': 'Principal Financial Officer & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 555993, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fabio  Cataldi M.D.', 'age': 56, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 516679, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rebecca  Mosig Ph.D.', 'title': 'Executive Director of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Josep  Bassaganya-Riera DVM, Ph.D.', 'age': 48, 'title': 'Advisor', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 1788694, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.57
currency§USD
dateShortInterest§1702598400
forwardEps§-2.61
exchange§NCM
quoteType§EQUITY
shortName§Landos Biopharma, Inc.
longName§Landos Biopharma, Inc.
firstTradeDateEpochUtc§1612449000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8d3ef42b-743e-3c42-a8bb-b248f7b0945c
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§5.0
targetMeanPrice§5.0
targetMedianPrice§5.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§7.63
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
